Source comparison
Tesamorelin for Anti-Aging Doctors: Comparison
The table below compares tesamorelin to other growth hormone modulation strategies used in anti-aging medicine. Focusing on mechanism, VAT selectivity, regulatory status, and practical constraints. Tesamorelin GHRH analogue. Stimulates endogenous GH 15–18% at
This comparison does not assign a generated winner or score.
- The table below compares tesamorelin to other growth hormone modulation strategies used in anti-aging medicine. Focusing on mechanism, VAT selectivity, regulatory status, and practical constraints.
- Tesamorelin
- GHRH analogue. Stimulates endogenous GH
- 15–18% at 26 weeks
- None. Preserves pulsatility
- FDA-approved (lipodystrophy), off-label for anti-aging
- 2 mg SC daily
- Best choice for VAT-specific reduction without suppressing natural GH axis
- CJC-1295 (DAC)
- Long-acting GHRH analogue
- Moderate. Less selective than tesamorelin
- Minimal if dosed correctly
- Not FDA-approved. Research use
- 1–2 mg SC weekly
- Longer half-life reduces injection frequency, but less clinical data on VAT specificity
- Ipamorelin
- GHRP. Stimulates GH via ghrelin receptor
- Minimal VAT selectivity
- None
- 200–300 mcg SC 2–3x daily
- More appetite stimulation, less VAT targeting. Used for anabolic effects, not fat loss
- Exogenous GH
- Direct GH replacement
- Moderate. Not VAT-selective
- Complete. Shuts down pituitary
- FDA-approved (deficiency only)
- 0.2–0.4 IU SC daily (anti-aging dose)
- Suppresses endogenous production; higher side-effect risk; no selectivity for visceral vs subcutaneous fat
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- Minimal. Increases appetite
- Not FDA-approved
- 12.5–25 mg orally daily
- Elevates GH and IGF-1 but stimulates appetite significantly. Net effect on VAT often neutral